NMDA antagonist effects on striatal dopamine release: Microdialysis studies in awake monkeys
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Brain imaging studies have suggested that the NMDA antagonist ketamine is as potent a releaser of striatal dopamine as amphetamine. This conclusion contradicts microdialysis findings in the rodent that NMDA antagonists, in contrast to amphetamine, have little or no effect on striatal dopamine release. The present study addressed two mechanisms that could account for this discrepancy: 1) whether there is a species difference, i.e., rodents vs. primates, in the responsivity of striatal dopamine to NMDA antagonists, and 2) whether rapid uptake of dopamine prevents reliable measures of synaptic dopamine release by microdialysis in response to NMDA antagonists. MRI‐directed in vivo microdialysis was used to compare the effects of psychotomimetic NMDA antagonists phencyclidine (PCP), ketamine, and amphetamine on extracellular striatal dopamine levels in awake rhesus monkeys. The effect of PCP was also investigated in the presence of intrastriatally applied nomifensine, a dopamine uptake blocker. Amphetamine (0.1 or 0.4 mg/kg) produced robust and dose‐dependent increases in dopamine release ranging 2–10‐fold above baseline. PCP at 0.1 mg/kg had no effect and at 0.3 mg/kg produced a small 50% increase over baseline. Ketamine, at the relatively high dose of 5 mg/kg, produced only a 30% increase in dopamine release. Intrastriatal application of nomifensine did not influence the effect of PCP, suggesting that rapid uptake of dopamine is not preventing the detection of a PCP‐induced increase in dopamine release. These findings suggest that in the primate, ketamine and PCP are not effective dopamine releasers, as has been suggested by previous imaging studies. Synapse 43:12–18, 2002. © 2002 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Laruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291 · cited 1×
“…NMDA antagonist ketamine, at behaviorally active subanesthetic doses (0.2–0.65 mg/kg), is a potent releaser of striatal dopamine because it produces a comparable displacement of a D2 receptor ligand, as do moderate doses (0.2–0.3 mg/kg) of amphetamine (Breier et al., 1997; Laruelle et al., 1996).”
InfluentialSchultz, W., Apicella, P., & Ljungberg, T. (1993) · The Journal of Neuroscience · doi:10.1523/jneurosci.13-03-00900.1993 · Cited by 1,291
Breier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154 · cited 2×
“Although it is difficult to determine “comparable” doses between different species, it is important to emphasize that the doses of amphetamine used here (0.1 and 0.4 mg/kg) are in the range of doses used in clinical studies (Breier et al., 1997; Kegeles et al., 2000; Laruelle et al., 1997).”
InfluentialRewarding Actions of Phencyclidine and Related Drugs in Nucleus Accumbens Shell and Frontal Cortex
Carlezon, & Wise, R. A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-09-03112.1996 · Cited by 327 · cited 1×
“…striatal (in particular, ventral striatal) dopamine activation for the reinforcing effects of psychoactive drugs (Wise et al., 1996), the rewarding and euphoric effects of NMDA antagonists are not blocked by dopamine antagonists in rodents (Carlezon and Wise, 1996) or humans (Krystal et al., 1999).”
Lynd-Balta, E., & Haber, S. N. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90182-1 · Cited by 233 · cited 1×
“…MRI scan to develop an individualized stereotaxic atlas that was used to determine the placement for an indwelling guide cannula, and subsequently the appropriate sites for placement of microdialysis probes into the brain region of interest (Haber and McFarland, 1999; Lynd-Balta and Haber, 1994).”
Bradberry, C. W., Barrett-Larimore, R. L., Jatlow, P., & Rubino, S. R. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-10-03874.2000 · Cited by 137 · cited 1×
“For a detailed description of procedures, such as the MRI scan, craniotomy, design of the dialysis probe and placement procedure, and maintenance of the preparation, see Bradberry et al. (2000).”
Self-citation
Cited by
Glutamate, Dopamine, and Schizophrenia: From Pathophysiology to Treatment
LARUELLE, M., KEGELES, L. S., & ABI‐DARGHAM, A. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.063 · Cited by 437
Models of schizophrenia in humans and animals based on inhibition of NMDA receptors
Bubeníková-Valešová, V., Horáček, J., Vrajová, M., & Höschl, C. (2008) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2008.03.012 · Cited by 336
Do the dissociative side effects of ketamine mediate its antidepressant effects?
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., Nolan, N. M., Richards, E. M., Brutsche, N. E., Guevara, S., & Zarate, C. A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.02.017 · Cited by 283
“However, Adams et al. (2002) found that ketamine did not stimulate dopamine release in non-human primates.”
The origin of NMDA receptor hypofunction in schizophrenia
Nakazawa, K., & Sapkota, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107426 · Cited by 275
Seneca, N., Finnema, S. J., Farde, L., Gulyás, B., Wikström, H. V., Halldin, C., & Innis, R. B. (2006) · Synapse · doi:10.1002/syn.20238 · Cited by 110
“Stimulation of DA release by ketamine has been shown to be selective to prefrontal cortex in rat (Verma and Moghaddam, 1996), with only negligible increases in monkey striatum (Adams et al., 2002).”
BackgroundInfluentialReduced presynaptic dopamine activity in adolescent dorsal striatum
Matthews, M., Bondi, C., Torres, G., & Moghaddam, B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.32 · Cited by 67
Self-citationvan Berckel, B. N. M., Kegeles, L. S., Waterhouse, R., Guo, N., Hwang, D.-R., Huang, Y., Narendran, R., Van Heertum, R., & Laruelle, M. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300902 · Cited by 43
“Three studies have reported an increase in amphetamine-induced DA release in patients with schizophrenia (”
BackgroundWitkin, J. M. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2020.172854 · Cited by 36
Metadata
- Authors
- Adams, B. W., Bradberry, C. W., & Moghaddam, B.
- Venue
- Synapse
- Publisher
- Wiley
- Published
- 2001-10-11
- Volume
- 43
- Issue
- 1
- Pages
- 12-18
- ISSN
- 0887-4476 (ISSN-L)
- 1098-2396
- OpenAlex
- W1966533161
- Cited by
- 58
- References
- 7
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.